Isis Pharmaceuticals Inc. Reaches New 12-Month High at $45.63 (ISIS)
Shares of Isis Pharmaceuticals (NASDAQ:ISIS) hit a new 52-week high during mid-day trading on Thursday, American Banking News reports. The stock traded as high as $45.63 and last traded at $45.58, with a volume of 1,424,863 shares trading hands. The stock had previously closed at $42.13.
ISIS has been the subject of a number of recent research reports. Analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note to investors on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. Analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note to investors on Thursday, November 7th. They now have a $33.00 price target on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. Isis Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $36.18.
In other Isis Pharmaceuticals news, SVP Richard Geary sold 15,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $40.45, for a total transaction of $606,750.00. Following the completion of the transaction, the senior vice president now directly owns 3,610 shares in the company, valued at approximately $146,025. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Isis Pharmaceuticals has a 52 week low of $12.08 and a 52 week high of $42.69. The stock has a 50-day moving average of $38.56 and a 200-day moving average of $32.81. The company’s market cap is $5.357 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last released its earnings data on Tuesday, November 5th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The company’s quarterly revenue was up 103.4% on a year-over-year basis. Analysts expect that Isis Pharmaceuticals will post $-0.52 EPS for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.